

Mohamed Shamji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8820650/publications.pdf>

Version: 2024-02-01

199
papers

8,659
citations

47409

49
h-index

58552

86
g-index

205
all docs

205
docs citations

205
times ranked

7216
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular allergology approach to allergic asthma. <i>Molecular Aspects of Medicine</i> , 2022, 85, 101027.	2.7	9
2	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	2.7	39
3	Mechanisms of Allergy. , 2022, , 435-447.		0
4	Current Drug Treatments for Allergy. , 2022, , 477-490.		1
5	The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2067-2079.	2.7	26
6	Milk allergy overdiagnosis. <i>Clinical and Experimental Allergy</i> , 2022, 52, 4-6.	1.4	2
7	Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 791-801.	1.5	50
8	Biomarker strategies for perioperative hypersensitivity reactions and severe eosinophilic asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 216-218.	1.4	0
9	Virus Like Particle (VLP) Based Peanut Allergen Immunotherapy Candidate Display A Decreased Activation And Histamine Release From CRTH2+ Basophils: A Proof of Concept Study. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, AB37.	1.5	0
10	Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1991-2024.	2.7	21
11	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
12	AllergoOncology: Danger signals in allergology and oncology: AA European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2594-2617.	2.7	5
13	Allergy in India a call for submissions. <i>Clinical and Experimental Allergy</i> , 2022, 52, 364-366.	1.4	0
14	Editorial: The Spectrum of Lymphoid Subsets in Allergic Diseases: Immune Regulation and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 869781.	2.2	0
15	Immune modulation and the role of innate immune cells in allergy and asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 474-475.	1.4	0
16	Allergen immunotherapy for asthma prevention: A systematic review and meta-analysis of randomized and non-randomized controlled studies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1719-1735.	2.7	29
17	Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2688-2698.	2.7	5
18	Early origins of allergic disease. <i>Clinical and Experimental Allergy</i> , 2022, 52, 592-594.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Cluster Analysis of Nasal Cytokines During Rhinovirus Infection Identifies Different Immunophenotypes in Both Children and Adults with Allergic Asthma. <i>Clinical and Experimental Allergy</i> , 2022, , .	1.4	3
20	Biomarkers of airway inflammation and immunotherapy. <i>Clinical and Experimental Allergy</i> , 2022, 52, 726-728.	1.4	0
21	Reply to correspondence: Basophil reactivity to BNT162b2 in COVID-19 convalescence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2266-2267.	2.7	1
22	Mechanisms and biomarkers of subcutaneous immunotherapy and sublingual immunotherapy in allergen immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 254-259.	1.0	5
23	Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 629-647.	2.7	31
24	EAACI Biologicals Guidelines—Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	2.7	156
25	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	2.7	46
26	ARIA—EAACI statement on asthma and COVID-19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	2.7	57
27	Uncovering the immunological properties of isolated lymphoid follicles. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1292-1293.	2.7	8
28	Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 663-676.	1.5	34
29	Mechanisms of Allergen Immunotherapy in Allergic Rhinitis. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 2.	2.4	67
30	Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1321-1324.	2.7	4
31	Cardiovascular changes during peanut-induced allergic reactions in human subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 633-642.	1.5	37
32	Allergy prevention. <i>Clinical and Experimental Allergy</i> , 2021, 51, 4-5.	1.4	1
33	What does climate change mean for people with pollen allergy?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 202-205.	1.4	0
34	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	6.6	134
35	Aetiology and prevention of eczema. <i>Clinical and Experimental Allergy</i> , 2021, 51, 380-381.	1.4	1
36	Innate lymphoid cells: The missing part of a puzzle in food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2002-2016.	2.7	18

#	ARTICLE	IF	CITATIONS
37	New innovations in allergy treatment and phenotyping. <i>Clinical and Experimental Allergy</i> , 2021, 51, 514-517.	1.4	0
38	Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908/1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 23-33.	2.5	40
39	What does it mean to be food allergic?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 634-635.	1.4	2
40	Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1061-1071.e11.	1.5	41
41	Real word evidence studies: Is it the way forward?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 748-750.	1.4	0
42	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1805-1812.	2.0	14
43	The role of allergen-specific IgE, IgG and IgA in allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3627-3641.	2.7	100
44	Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1769-1778.	2.0	52
45	Biological treatment in allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2934-2937.	2.7	6
46	Evidence Synthesis in Allergy – A call for submissions. <i>Clinical and Experimental Allergy</i> , 2021, 51, 868-869.	1.4	0
47	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1640-1660.	2.7	72
48	ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	1.4	24
49	EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1629-1639.	2.7	99
50	ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	2.7	66
51	Biomarkers in asthma and allergic diseases. <i>Clinical and Experimental Allergy</i> , 2021, 51, 982-984.	1.4	1
52	Asthma management and impact on COVID-19 outcomes. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1100-1102.	1.4	1
53	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	2.7	16
54	Allergy societies and the formula industry. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1260-1261.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. <i>JAMA Network Open</i> , 2021, 4, e2125524.	2.8	103
56	Dogmas, challenges, and promises in phase III allergen immunotherapy studies. <i>World Allergy Organization Journal</i> , 2021, 14, 100578.	1.6	3
57	Unmet needs in food allergy. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1258-1259.	1.4	1
58	Making causal inferences in allergy epidemiology studies. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1404-1406.	1.4	0
59	Developments in the field of allergy in 2020 through the eyes of <i>Clinical and Experimental Allergy</i> . <i>Clinical and Experimental Allergy</i> , 2021, 51, 1531-1537.	1.4	1
60	Allergic diseases and novel targets in allergen immunotherapy. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1526-1528.	1.4	2
61	Prize-winning abstracts from BSACI 2021 meeting. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1529-1530.	1.4	2
62	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	1.5	272
63	Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 180-191.	1.5	46
64	Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1005-1007.e7.	1.5	35
65	Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1780-1783.	2.7	6
66	Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 599083.	2.2	68
67	AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Clinical and Translational Allergy</i> , 2020, 10, 32.	1.4	40
68	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 457-458.	1.5	1
69	Allergen Immunotherapy in Children User's Guide. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 1-101.	1.1	169
70	Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1585-1597.	1.5	23
71	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	2.7	67
72	Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 238.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Nasal Allergen Neutralizing Antibodies Correlate Closely with Tolerated Intranasal Allergen Challenge Dose Following Grass Pollen Subcutaneous Immunotherapy in Patients with Local Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB184.	1.5	0
74	Allergenicity and Safety Profile of Depigmented-Polymerized Phleum pratense Extract for Use in Allergen-Specific Immunotherapy Treatments. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB60.	1.5	0
75	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives”A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2445-2476.	2.7	132
76	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	2.7	232
77	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ”recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	2.7	85
78	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1899-1901.	2.7	3
79	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	2.7	87
80	The emerging role of T follicular helper (TFH) cells in aging: Influence on the immune frailty. <i>Ageing Research Reviews</i> , 2020, 61, 101071.	5.0	36
81	In”vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan”An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	2.7	23
82	Local allergic rhinitis: Implications for management. <i>Clinical and Experimental Allergy</i> , 2019, 49, 6-16.	1.4	86
83	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases”Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	0.6	11
84	Pharmacometabolomics of Bronchodilator Response in Asthma and the Role of Age-Metabolite Interactions. <i>Metabolites</i> , 2019, 9, 179.	1.3	13
85	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases”Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	0.6	15
86	Role of IL-35 in sublingual allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 12-17.	1.1	27
87	Mucosal IgE immune responses in respiratory diseases. <i>Current Opinion in Pharmacology</i> , 2019, 46, 100-107.	1.7	21
88	Measurement of Allergen-Specific Inhibitory Antibody Activity. <i>Methods in Molecular Biology</i> , 2019, 2020, 33-43.	0.4	2
89	Successful Desensitisation And Sustained Unresponsiveness Using Modified Peanut: Results From The BOPI Study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB82.	1.5	2
90	Prioritizing research challenges and funding for allergy and asthma and the need for translational research”The European Strategic Forum on Allergic Diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2064-2076.	2.7	39

#	ARTICLE	IF	CITATIONS
91	Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1067-1076.	1.5	90
92	Broad IgG repertoire in patients with chronic rhinosinusitis with nasal polyps regulates proinflammatory IgE responses. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2086-2094.e2.	1.5	27
93	Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1575-1579.	2.7	16
94	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	2.7	140
95	Immunologic mechanisms of a short-course of <i>Lolium perenne</i> peptide immunotherapy: A randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 738-749.	1.5	35
96	Nasal IgE production in allergic rhinitis: Impact of rhinovirus infection. <i>Clinical and Experimental Allergy</i> , 2019, 49, 847-852.	1.4	3
97	Lipid Transfer Protein allergy in the United Kingdom: Characterization and comparison with a matched Italian cohort. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1340-1351.	2.7	50
98	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	2.7	113
99	Role of IL-35 in sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1131-1142.e4.	1.5	82
100	ARIA-Versorgungspfade für die Allergenimmuntherapie 2019. <i>Allergologie</i> , 2019, 42, 404-425.	0.1	2
101	Mast cell activation test in the diagnosis of allergic disease and anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 485-496.e16.	1.5	119
102	<i>Lolium perenne</i> peptide immunotherapy is well tolerated and elicits a protective B cell response in seasonal allergic rhinitis patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1254-1262.	2.7	28
103	Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1842-1850.	2.7	44
104	<i>Lolium perenne</i> peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 448-451.	1.5	18
105	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 837-850.	2.7	79
106	Perspectives in allergen immunotherapy: 2017 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-23.	2.7	76
107	Antiapoptotic serine protease inhibitors contribute to survival of allergenic TH2 cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 569-581.e5.	1.5	13
108	Synchronous immune alterations mirror clinical response during allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1750-1760.e1.	1.5	61

#	ARTICLE	IF	CITATIONS
109	A randomized, double-blind, placebo-controlled, dose-finding trial with <i>Lolium perenne</i> peptide immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 896-904.	2.7	31
110	Quality of Life during the hay fever season after short-course subcutaneous immunotherapy with <i>Lolium perenne</i> peptides (LPP) in grass pollen related rhinoconjunctivitis: A RDBPCT. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB291.	1.5	0
111	IgE Test in Secretions of Patients with Respiratory Allergy. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 67.	2.4	22
112	Short Course of <i>Lolium Perenne</i> Peptides (LPP) Immunotherapy Deletes Circulating IL-4 + IL-21 + T follicular helper cells and Induces FoxP3 + T follicular regulatory cells: A Randomized Controlled Trial. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB197.	1.5	0
113	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1019.	1.5	0
114	Biomarker bei der Allergen-Immuntherapie – ein EAACI Positionspapier. <i>Allergologie</i> , 2018, 41, 376-385.	0.1	0
115	Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1156-1173.	2.7	275
116	Genome-wide interaction study of dust mite allergen on lung function in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 996-1003.e7.	1.5	25
117	Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 615.	3.8	166
118	Surfactant Protein-D (SP-D): a Potential Therapeutic Target for Seasonal Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB84.	1.5	1
119	SATB1 is repressed in FoxP3+Tregs following Grass Pollen Subcutaneous and Sublingual Immunotherapy and Correlates with Clinical efficacy. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB192.	1.5	2
120	Response to Nasal Challenge Correlates with Seasonal Outcomes during Grass Pollen Immunotherapy with Either Subcutaneous or Sublingual Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB385.	1.5	0
121	Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy. <i>Current Treatment Options in Allergy</i> , 2017, 4, 43-53.	0.9	31
122	Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 750-758.e15.	1.5	56
123	A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation and T-Helper Type 2 and B-Cell Responses in Grass Pollen-induced Allergic Inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1526-1534.	2.5	20
124	Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1485-1498.	1.5	323
125	Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1830-1839.e13.	1.5	35
126	Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 73-86.	1.0	67

#	ARTICLE	IF	CITATIONS
127	Analysis of the Interaction between Globular Head Modules of Human C1q and Its Candidate Receptor gC1qR. <i>Frontiers in Immunology</i> , 2016, 7, 567.	2.2	16
128	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. <i>Clinical and Translational Allergy</i> , 2016, 6, 41.	1.4	24
129	Facilitated Allergen Binding (FAB) Is a Meaningful Immunological Biomarker for Monitoring Immediate Clinical Efficacy in Short-Term Peptide Allergen Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB403.	1.5	1
130	Intracellular Expression of Fluorochrome Labelled-Diamine Oxidase in Basophils: A Novel Diagnostic Tool for Peanut Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB137.	1.5	0
131	Randomised Placebo-Controlled Trial of Grass Pollen Allergen Tablet Immunotherapy for Seasonal Rhinitis: Clinical and Surrogate Outcomes and Early Time Course of Immunologic Changes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB197.	1.5	0
132	Group 2 Innate Lymphoid Cells: New Players in Peanut Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB74.	1.5	1
133	T follicular helper (T _{fh}) cells in normal immune responses and in allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1086-1094.	2.7	82
134	Epitope specificity determines cross-protection of a SIT ⁺ -induced IgG ₄ antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 36-46.	2.7	16
135	A Randomized Placebo-Controlled Trial of Intradermal Grass Pollen Immunotherapy for Seasonal Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB94.	1.5	0
136	Complement Deposition on Nanoparticles Can Modulate Immune Responses by Macrophage, B and T Cells. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 197-216.	0.5	15
137	Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 452-461.e9.	1.5	48
138	A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis. <i>Efficacy and Mechanism Evaluation</i> , 2016, 3, 1-80.	0.9	1
139	Immunogenicity Evaluation of Subcutaneous Administration of Peptide Hydrolysate from <i>Lolium Perenne</i> (gpASIT ₊) in Combination with Bacterial HSP70 (DnaK) in Patients with Seasonal Allergic Rhinitis: A Double Blind Placebo Controlled Trial. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB159.	1.5	0
140	Marked Increase in Basophil Activation during Non-Anaphylactic Allergic Reactions to Peanut in Man. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB33.	1.5	3
141	Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 689-696.	2.7	71
142	Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes. <i>Clinical and Translational Allergy</i> , 2015, 5, 43.	1.4	6
143	Immunomodulatory effects of IL-27 on allergen-induced Th2 responses. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2015, 33, 15-16.	0.0	0
144	Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 171-179.	2.7	29

#	ARTICLE	IF	CITATIONS
145	Stress and Bronchodilator Response in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 47-56.	2.5	99
146	IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. Journal of Allergy and Clinical Immunology, 2015, 135, 1249-1256.	1.5	207
147	Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response. Journal of Allergy and Clinical Immunology, 2015, 135, 913-921.e9.	1.5	101
148	Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity. Journal of Allergy and Clinical Immunology, 2015, 136, 885-892.e2.	1.5	51
149	Innate immune humoral factors, C1q and factor H, with differential pattern recognition properties, alter macrophage response to carbon nanotubes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2109-2118.	1.7	34
150	Asthma in Latin America. Thorax, 2015, 70, 898-905.	2.7	68
151	Reply. Journal of Allergy and Clinical Immunology, 2015, 135, 1089-1090.	1.5	0
152	Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 720-724.	2.7	52
153	Local and systemic effects of cat allergen nasal provocation. Clinical and Experimental Allergy, 2015, 45, 613-623.	1.4	36
154	IL-35-Producing T Cells (iTR35) Inhibit Th2 Effector Function, Induce Infectious Tolerance and Are Elevated Following Grass Pollen Sublingual Immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, AB51.	1.5	1
155	Grass Pollen Immunotherapy: Impaired Allergen-Induced Nasal and Cutaneous Responses Correlate With Overall Seasonal Symptom Scores and Are Associated With Suppressed Local Th2 Cytokines In Nasal Fluid. Journal of Allergy and Clinical Immunology, 2014, 133, AB158.	1.5	0
156	IL-10-Producing B Cells Are Increased After Grass Pollen Immunotherapy Compared To Untreated Grass Pollen Allergic Controls: A Blinded Cross-Sectional Study. Journal of Allergy and Clinical Immunology, 2014, 133, AB53.	1.5	0
157	Development of cockroach immunotherapy by the Inner-City Asthma Consortium. Journal of Allergy and Clinical Immunology, 2014, 133, 846-852.e6.	1.5	48
158	Mechanisms of Allergen-Specific Sublingual Immunotherapy and the Use of Biological Markers in Allergic Rhinitis. Current Treatment Options in Allergy, 2014, 1, 1-13.	0.9	1
159	Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, 468-475.e6.	1.5	375
160	Allergen-specific IgE is not detectable in the bronchial mucosa of nonatopic asthmatic patients. Journal of Allergy and Clinical Immunology, 2014, 133, 1770-1772.e11.	1.5	24
161	A genome-wide survey of CD4+ lymphocyte regulatory genetic variants identifies novel asthma genes. Journal of Allergy and Clinical Immunology, 2014, 134, 1153-1162.	1.5	46
162	Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 134, 1193-1195.e4.	1.5	166

#	ARTICLE	IF	CITATIONS
163	Rat-specific IgG and IgG₄antibodies associated with inhibition of IgE-allergen complex binding in laboratory animal workers. Occupational and Environmental Medicine, 2014, 71, 619-623.	1.3	17
164	Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy. Journal of Allergy and Clinical Immunology, 2014, 134, 751-753.	1.5	48
165	Interleukin IL-27+ Dendritic Cells Modulate Ex-Vivo Th2 Responses In a Pdl-1-Dependent Manner and Increase In-Vivo Following Grass Pollen Immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, AB157.	1.5	0
166	Interleukin 35 Modulates TSLP, IL-25 and IL-33 Primed Dendritic Cells and Inhibits Naive T Cell Differentiation and Grass Pollen-Specific T Cell Proliferation. Journal of Allergy and Clinical Immunology, 2014, 133, AB149.	1.5	0
167	Local 'Protective' IgG4 Antibodies In Nasal Fluid Are Elevated Following Grass Pollen Immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, AB157.	1.5	0
168	Native American Ancestry, Lung Function, and COPD in Costa Ricans. Chest, 2014, 145, 704-710.	0.4	23
169	Grass pollen nasal challenge is associated with increases in Th2 cytokines, Eotaxin, MDC and IL-6 in nasal fluid. Clinical and Translational Allergy, 2013, 3, P29.	1.4	2
170	Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clinical and Translational Allergy, 2013, 3, 27.	1.4	6
171	Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. Journal of Allergy and Clinical Immunology, 2013, 131, 1419-1421.	1.5	45
172	Immunomodulatory Effects of IL-27 On Allergen-Induced Th2 Responses. Journal of Allergy and Clinical Immunology, 2013, 131, AB203.	1.5	4
173	Grass Pollen Allergics Have Fewer IL-10-Producing B Cells Than Non-Atopic Controls. Journal of Allergy and Clinical Immunology, 2013, 131, AB204.	1.5	0
174	Local Nasal 'Protective' Immunoglobulin G4 (IgG4) Responses in Nasal Fluid Following Grass Pollen Sublingual Immunotherapy. Journal of Allergy and Clinical Immunology, 2013, 131, AB202.	1.5	2
175	Detection and Quantitation of Total and Allergen-Specific IgE in the Bronchial Mucosa of Atopic and Non-Atopic Asthmatics. Journal of Allergy and Clinical Immunology, 2013, 131, AB331.	1.5	0
176	IL-35+ Regulatory T Cells Suppress Grass Pollen-Driven Th2 Responses and Are Induced Following Grass Pollen-Specific Sublingual Immunotherapy. Journal of Allergy and Clinical Immunology, 2013, 131, AB146.	1.5	3
177	Linking surfactant protein SP-D and IL-13: Implications in asthma and allergy. Molecular Immunology, 2013, 54, 98-107.	1.0	33
178	Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: Inhibition by blocking antibody responses after immunotherapy. Journal of Allergy and Clinical Immunology, 2013, 132, 1003-1005.e4.	1.5	51
179	Allergen Immunotherapy and Tolerance. Allergology International, 2013, 62, 403-413.	1.4	88
180	Predictive biomarkers of clinical efficacy of allergen-specific immunotherapy: how to proceed. Immunotherapy, 2013, 5, 203-206.	1.0	18

#	ARTICLE	IF	CITATIONS
181	A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreSâ€Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. <i>Journal of Immunology</i> , 2013, 190, 3068-3078.	0.4	57
182	Linking surfactant protein SP-D and IL-13: Implications in asthma and allergy. <i>Molecular Immunology</i> , 2013, 54, 98-107.	1.0	25
183	High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1499-1505.e5.	1.5	171
184	Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 663-670.e3.	1.5	77
185	Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 918-924.e1.	1.5	37
186	Superparamagnetic iron oxide nanoparticles conjugated to a grass pollen allergen and an optical probe. <i>Contrast Media and Molecular Imaging</i> , 2012, 7, 435-439.	0.4	9
187	Functional rather than immunoreactive levels of IgG₄ correlate closely with clinical response to grass pollen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 217-226.	2.7	254
188	Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 509-516.e5.	1.5	299
189	Petasol butenoate complex (Ze 339) relieves allergic rhinitisâ€Finduced nasal obstruction more effectively than desloratadine. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1515-1521.e6.	1.5	26
190	Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 311-323.	0.7	37
191	Long-term clinical and immunological effects of allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 586-593.	1.1	76
192	Mechanisms of immunotherapy to aeroallergens. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1235-1246.	1.4	131
193	Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. <i>BMC Medical Genetics</i> , 2011, 12, 26.	2.1	25
194	Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3â€Fexpressing cells and elevated allergenâ€Fspecific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin Eâ€Ffacilitated allergen binding to B cells. <i>Clinical and Experimental Allergy</i> , 2010, 40, 598-606.	1.4	209
195	Inhibition of CD23â€Fdependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. <i>Clinical and Experimental Allergy</i> , 2010, 40, 1346-1352.	1.4	31
196	Blocking Antibodies: Relationship between IgG4-associated Inhibitory Activity and Clinical Response to Grass-Pollen Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, AB131.	1.5	2
197	CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 118-125.	1.0	22
198	HIV-1 Viral Replication below 50 Copies/ml in Patients on Antiretroviral Therapy is not associated with CD8⁺ T-cell Activation. <i>Antiviral Therapy</i> , 2007, 12, 971-976.	0.6	18

#	ARTICLE	IF	CITATIONS
199	The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. Journal of Immunological Methods, 2006, 317, 71-79.	0.6	138